-
Product Insights
Slate Solar PV Park
Slate Solar PV Park is a solar PV project located in California, United States. The project is owned by MN8 Energy LLC and was developed by MN8 Energy LLC; Recurrent Energy LLC. The project came online in 2022. Empower your strategies with our Slate Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase,...
-
Product Insights
NewNet Present Value Model: Gritstone Bio Inc’s SLATE-001
Empower your strategies with our Net Present Value Model: Gritstone Bio Inc's SLATE-001 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Sector Analysis
Polyethylene Terephthalate (PET) Industry Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants to 2028
Polyethylene Terephthalate (PET) Industry Capacity & CapEx Overview The polyethylene terephthalate (PET) industry capacity was 36.23 million tonnes per annum (mtpa) in 2023 and is expected to increase at an AAGR of more than 3% during 2023-2028. Around 17 planned and announced plants are slated to come online by 2028, primarily in Asia, Middle East and the Former Soviet Union (FSU). Additionally, the growing consumption of PET in packaging, food and beverage, as well as in textile industry will drive...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLATE-001 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Solid Tumor Drug Details: SLATE-001 is under development for the...
-
Sector Analysis
Ethylene Glycol Industry Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants to 2028
Ethylene Glycol Industry Capacity & CapEx Overview The Ethylene Glycol industry capacity was 60.06 million tonnes per annum (mtpa) in 2023 and it is expected to increase at an AAGR of more than 5% during 2023-2028. Around 40 planned and announced plants are slated to come online by 2028, primarily in Asia and the Middle East. This will boost the market growth during the forecast years. Ethylene Glycol Industry Capacity and CapEx Outlook, 2023-2028 (mtpa) Buy the Full Report for...
-
Product Insights
NewLupus Nephritis – Drugs In Development, 2024
Empower your strategies with our Lupus Nephritis – Drugs In Development, 2024 report and make more profitable business decisions. Lupus nephritis is a severe complication of systemic lupus erythematosus (SLE), an autoimmune disease that affects various organs, tissues, and systems within the body. Lupus nephritis specifically involves inflammation of the kidneys, leading to kidney damage and impaired kidney function. In systSLE, the body's immune system mistakenly attacks its own tissues and organs, including the kidneys, causing inflammation. Not all individuals with...
-
Product Insights
NewIschemia Reperfusion Injury – Drugs In Development, 2024
Empower your strategies with our Ischemia Reperfusion Injury – Drugs In Development, 2024 report and make more profitable business decisions. Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension,...
-
Product Insights
NewGlomerulonephritis – Drugs In Development, 2024
Empower your strategies with our Glomerulonephritis – Drugs In Development, 2024 report and make more profitable business decisions. Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat (strep throat), immune diseases such as lupus, type 1 and type 2 diabetes, and viral infections such as HIV, hepatitis B virus, and hepatitis C virus. Risk factors include family...
-
Product Insights
NewAcute Renal Failure (ARF) (Acute Kidney Injury) – Drugs In Development, 2024
Empower your strategies with our Acute Renal Failure (ARF) (Acute Kidney Injury) – Drugs In Development, 2024 report and make more profitable business decisions. Acute renal failure occurs when the kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases, and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure, and kidney diseases. Treatment includes antibiotics and diuretics. The Acute Renal Failure (ARF) (Acute...